Bristol Myers Squibb Tops Q4 Estimates

[cafead]

via

• Adjusted EPS of $1.67 beat expectations of $1.46.
• Revenue rose to $12.3 billion, exceeding estimates of $11.57 billion.
• The growth portfolio of drugs saw a 21% revenue increase, driven by Reblozyl, Breyanzi, and Camzyos.

article source